Q1 FY27 results analysis · July 31, 2026

Alivus Life Sciences Ltd Q1 FY27 Results Analysis: EBITDA Margin Expands 650 bps, PAT Jumps 31.7%

+31.7%PAT year on year, Rs. 160.08 Cr
Cofacto ResearchPublished July 31, 20262 min readPositive read
Quick summary

Alivus Life Sciences Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 640.41 Cr (+6.40% YoY) and PAT growth of +31.70% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 30, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 640.41 Cr (+6.40% YoY)
PAT (Q1)Rs. 160.08 Cr (+31.70% YoY)
EBITDA margin36.60% (+650 bps YoY)
EPS (Q1)Rs. 13.04 (+31.60% YoY)
Market capRs. 13,448.56 Cr
CMPRs. 1,095.70

Quarter Snapshot

Alivus delivered a strong margin beat with EBITDA margin expanding 650 bps YoY to 36.6%, well above the 30-32% guidance band, driven by a 520 bps improvement in material costs. PAT grew 31.7% YoY, though revenue growth of 6.4% was at the lower end of the high single-digit guidance, and QoQ revenue declined 7.1% due to GPL volatility. The debt-free balance sheet and structural margin improvement provide a solid foundation, but revenue acceleration in H2 is needed to meet full-year guidance.

Key Investment Insights

Key Positives

  • EBITDA margin expanded 650 bps YoY to 36.6%, the highest in five quarters
  • Operating EBITDA margin (ex-other income) expanded 450 bps YoY to 33.1%, confirming structural improvement
  • PAT grew 31.7% YoY to Rs.160.08 Cr, with EPS rising 31.6% to Rs.13.04
  • Material cost ratio improved 520 bps YoY to 39.5% of revenue, driving margin expansion
  • Debt-free balance sheet with Rs.782.40 Cr cash as of March 31, 2026

Risk Factors

  • Revenue declined 7.1% QoQ from Q4FY26 peak, consistent with GPL business volatility
  • Revenue growth of 6.4% is at the lower end of the high single-digit guidance range, requiring acceleration in H2 to meet full-year guidance

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.